메뉴 건너뛰기
Expert Opinion on Pharmacotherapy
Volumn 11, Issue 4, 2010, Pages 685-687
Insights from the dabigatran versus warfarin in patients with atrial fibrillation (RE-LY) trial
Author keywords

Atrial fibrillation; Dabigatran; Direct thrombin inhibitor; Stroke
Indexed keywords

DABIGATRAN; WARFARIN;
EID: 77249105085     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560903530691     Document Type: Note
Times cited : (3)
References (7)
  • 1
    • 70349306707 scopus 로고    scopus 로고
    • the RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation (RE-LY, NCT00262600)
    • Connolly SJ, Ezekowitz MD, Yusuf S, et al.; the RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation (RE-LY, NCT00262600). N Engl J Med 2009;361:1139-51
    • (2009) N Engl J Med , vol.361 , pp. 1139-1151
    • Connolly, S.J.1    Ezekowitz, M.D.2    Yusuf, S.3
  • 2
    • 4644230820 scopus 로고    scopus 로고
    • Ansell J, Hirsh J, Poller L, et al. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:2045-335
    • Ansell J, Hirsh J, Poller L, et al. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:2045-335
  • 3
    • 33845718250 scopus 로고    scopus 로고
    • Euro Heart Survey Investigators. Antithrombotic treatment in real-life atrial fibrillation patients: A report from the Euro Heart Survey on Atrial Fibrillation
    • Nieuwlaat R, Capucci A, Lip GY, et al.; Euro Heart Survey Investigators. Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2006;27:3018-26
    • (2006) Eur Heart J , vol.27 , pp. 3018-3026
    • Nieuwlaat, R.1    Capucci, A.2    Lip, G.Y.3
  • 4
    • 4644349854 scopus 로고    scopus 로고
    • Oral direct thrombin inhibition: An effective and novel approach for venous thromboembolism
    • Haas S. Oral direct thrombin inhibition: an effective and novel approach for venous thromboembolism. Drugs 2004;64:7-16
    • (2004) Drugs , vol.64 , pp. 7-16
    • Haas, S.1
  • 5
    • 34548031359 scopus 로고    scopus 로고
    • The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects
    • Stangier J, Rathgen K, Stahle H, et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007;64:292-303
    • (2007) Br J Clin Pharmacol , vol.64 , pp. 292-303
    • Stangier, J.1    Rathgen, K.2    Stahle, H.3
  • 6
    • 64349107688 scopus 로고    scopus 로고
    • Rationale and design of RE-LY: Randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran
    • Ezekowitz MD, Connolly S, Parekh A, et al. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J 2009;157:805-10
    • (2009) Am Heart J , vol.157 , pp. 805-810
    • Ezekowitz, M.D.1    Connolly, S.2    Parekh, A.3
  • 7
    • 33748646566 scopus 로고    scopus 로고
    • Clinical trial design issues: At least 10 things you should look for in clinical trials
    • Glasser SP, Howard G. Clinical trial design issues: at least 10 things you should look for in clinical trials. J Clin Pharmacol 2006;46:1106-15
    • (2006) J Clin Pharmacol , vol.46 , pp. 1106-1115
    • Glasser, S.P.1    Howard, G.2

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.